Objective: Lipid disturbances following treatment with second-generation antipsychotics (SGA) represent a major health concern. A previous study determined that early changes of plasma lipid levels ≥5% during the first month of treatment with SGA predicts further lipid worsening and development of dyslipidemia. This study aimed to determine the proportion of adolescents with early lipid changes ≥5% and who develop dyslipidemia during SGA treatment. Methods:
INTRODUCTION
Patients suffering from severe mental illness such as schizophrenia, bipolar disorder, and major depressive disorders have a 10-to 25-year reduced life expectancy compared to individuals from the general population [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] , which is mainly attributable to cardiovascular diseases resulting from the metabolic syndrome 11 . Multiple risk factors implying complex mechanisms may explain this excessive susceptibility for developing cardiovascular diseases, including psychiatric disease-related factors, an unhealthy lifestyle, poverty, and adverse effects of treatment 12, 13 . Thus, although commonly prescribed to reduce psychotic and manic symptoms of schizophrenia and bipolar disorders, the use of psychotropic medications such as antipsychotics (most atypical but also some typical), mood stabilizers (e.g., lithium and valproate) and some antidepressants (e.g., mirtazapine) can increase the risk of metabolic disorders, including obesity and dyslipidemia 14, 15 . Multiple factors have been associated with psychotropic drug-induced metabolic complications, including low baseline BMI, young age and no previous exposure to any psychotropic drug, making adolescents particularly susceptible to the development of adverse metabolic effects 13, 16 . In addition, some studies, albeit controversial, suggested that women have a greater vulnerability to psychotropic druginduced weight gain than men 12, 17 .
Adverse metabolic effects such as weight gain are difficult to manage and can have potential long-term cardiometabolic consequences, especially in young patients 16, [18] [19] [20] .
Other metabolic parameters (e.g. lipid profile) can also be worsened in young patients treated with antipsychotics, 19, [21] [22] [23] [24] which dramatically enhances the risk for long-term cardiovascular morbidity and mortality 25 . Thus, the propensity to develop dyslipidemia (defined as high total cholesterol (TC) and/or high LDL-cholesterol (LDL-C), and/or low HDL-cholesterol (HDL-C) and/or high non-HDL cholesterol (non-HDL-C) and/or high triglyceride (TG) levels) in a young patient who receives an antipsychotic medication was estimated to be two-to threefold higher than in a patient who does not receive this type of medication 26 . In addition, this metabolic condition was shown to reach 55% in patients with first episode schizophrenia who receive antipsychotic treatment 27 . Therefore, regular monitoring for metabolic parameters in patients receiving the abovementioned drugs is an important issue. Some programs have proposed monitoring of metabolic parameters during treatment in patients receiving psychotropic drugs known to induce metabolic disturbances, including a close monitoring during the first three months of treatment 28, 29 .
Recent studies recognized that components of the metabolic syndrome may develop early during psychotropic treatment and may initiate a steady process leading to cardiometabolic diseases in the long term 19, 20, [30] [31] [32] . In particular, lipogenic adverse effects may occur very early during treatment and may even precede weight gain 13, 19, [33] [34] [35] . Our research group recently demonstrated the importance of early (i.e., after one month of treatment) changes of lipid levels to predict worsening of the lipid profile and development of dyslipidemia in the longer term of treatment (≥3 months of treatment) 31 . In particular, patients whose lipid levels increased by 5% or more during the first month of psychotropic treatment were more prone to have a considerable worsening of their lipid profiles after three months of treatment and to develop dyslipidemia, as compared to other patients 31 .
Interestingly, these early lipid-change predictors were applicable in age-stratified samples, showing an age-independence and suggesting that they were also valid in adolescent patients. However, further characterization of lipid-profile worsening in adolescents could not be assessed due to an insufficient number of patients ≤ 18 years (n = 16). Although some prospective studies observed that some antipsychotics (e.g., olanzapine, quetiapine, or risperidone) induced significant lipid abnormalities in children and adolescents 19, 36, 37 , plasma lipid levels were not measured in the early period of treatment (i.e., within the first month), which would have been beneficial.
Because of the high morbidity and mortality associated with dyslipidemia, an early detection of adolescent patients at risk for developing lipid disturbances during psychotropic treatment is of major clinical concern. The aim of the present study was to determine the proportion of patients with early lipid change ≥5% and to measure the incidence of new onset dyslipidemia during treatment with psychotropic drugs. Our secondary purpose was to identify demographic and clinical risk factors associated with worsening of the lipid profile.
METHODS

Study design
A longitudinal observational study has been ongoing since 2007 in the Department of Psychiatry of the Lausanne University Hospital
38
. Patients starting a pharmacological treatment that is known to have a potential risk to induce metabolic disturbances (i.e.
an antipsychotic, mood stabilizer or antidepressant listed in Supplementary Table 1) were included, as described in the flowchart (Supplementary Figure 1) . The present study included patients with informed consent from an ongoing pharmacogenetic study (PsyMetab) as described elsewhere 39 . In addition, data of patients in the clinical followup (PsyClin) in our department were also analyzed. Due to the noninterventional post hoc analysis study design, no informed consent was requested from the patients who Supplementary Table 2) were included in the sample used for descriptive statistics of early lipid changes (i.e., data 1; n = 53). Of note, 63% of patients were not drug naïve.
Patients whose lipid levels were available at baseline, at first month, and later during treatment (median of 92 days, IQR: 80-101, range 56-447) and who did not meet criteria for dyslipidemia at baseline were included in the second sample, which was used to describe the development of dyslipidemia during psychotropic treatment in function of lipid changes at first month (i.e., data 2; n ≤ 25). The majority of blood samples were drawn in the morning in fasting conditions. Non-fasting blood samples (i.e. within 6 hours following the last meal) were excluded only for triglyceride (TG) analysis (not for total (TC), HDL-(HDL-C), LDL-(LDL-C) and non-HDL-(non-HDL-C) cholesterol) 40, 41 . As mentioned previously, 16 patients ≤ 18 years included in the present study were already included in a recent study designed to determine the best early thresholds for predicting further important lipid worsening 31 . However, this number was insufficient to conduct additional analyses specifically in young patients.
The present study design enabled to include a greater number of participants (i.e., 37 new patients, for a total of 53).
Quantification of plasma lipids
Clinical chemistry assays from plasma samples collected before and after January 2009 were performed at the Unit of Pharmacogenetics and Clinical Psychopharmacology and at the Clinical Laboratory of the Lausanne University Hospital, respectively (both laboratories are ISO 15189 certified), using enzymatic colorimetric assays (Roche Modular P chemistry analyzer, Roche Diagnostics, Basel, Switzerland, respectively).
Coefficients of variation for these assays were of ≤1.6%, ≤2% and ≤2.8% for TC, TG and HDL-C measurements, respectively. Low HDL-cholesterol level, i.e. HDL hypocholesterolemia was defined as < 1 mmol/l, high LDL-cholesterol level, i.e. LDL hypercholesterolemia was defined as ≥ 3 mmol/l, high triglyceride level, i.e. hypertriglyceridemia was defined as ≥ 2 mmol/l and high total cholesterol level, i.e. hypercholesterolemia was defined as ≥ 5 mmol/l, according to ESH/ESC guidelines 42 . LDL-C was calculated using the Friedewald formula only when TG levels were lower than 3.5 mmol/l (310 mg/dL) 43, 44 . Non-HDL-C was calculated from TC minus HDL-C.
Statistical analyses
In order to compare distribution of demographic and clinical variables across patient's groups, Wilcoxon-Mann-Whitney rank-sum tests and chi-squared tests were 
Short-and long-term lipid changes
The influence of early lipid changes on long-term lipid changes was estimated by fitting linear mixed effect models on long-term lipid changes adjusting for age, gender and early weight gain groups (>4% versus ≤4%
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) .
Short-term lipid changes and new-onset dyslipidemia
Kaplan-Meier estimates with log-rank tests were conducted to compare the incidence of new-onset dyslipidemia across patients with or without early lipid change ≥5%. For survival multivariate analyses, Cox regression tests were conducted, adjusting for age, gender, psychotropic drug category (olanzapine and quetiapine being associated with the highest risk of dyslipidemia; other drugs conferring a moderate risk were the most frequent diagnosis (43%). Quetiapine was the most frequently prescribed psychotropic drug (62%), followed by risperidone (23%), olanzapine (13%) and amisulpride (2%). Eight out of the 53 patients (15%) received two SGAs.
RESULTS
Demographics and evolution of lipid parameters
Seventeen percent of patients had hypercholesterolemia at baseline, i.e. TC ≥5 mmol/l (no patient received any lipid-lowering drug). Of note, in a sample including a higher number of patients (with lipid levels not systematically collected after one month of treatment (n=111), hypercholesterolemia prevalence was similar (i.e. 15.3%). In the present sample of 53 patients, 26 (49%), 23 (43%), 19 (36%), 15 (28%), and 24 patients (45%) had early changes of ≥ 5% for TC, LDL-C, TG, HDL-C, and non-HDL-C, respectively during the first month of SGA treatment. More information in Appendix 1.
A gender comparison of demographic and of clinical parameters is shown in
Supplementary Table 3. After the first month of SGA treatment, the prevalence of hypercholesterolemia was significantly higher for females than for males (38% versus 13%; p = 0.04). Similarly, females had significantly higher levels of total cholesterol compared to males, both before and after one month of treatment (4.3 mmol/l versus 3.6 mmol/l; p = 0.02; 4.4 mmol/l versus 3.8 mmol/l; p = 0.004). Finally, quetiapine was more prescribed for females than for males (76% vs 46%; p = 0.02).
Influence of short-term lipid changes on long-term lipid changes
Linear mixed models adjusting for age, gender, early weight gain group (i.e., >4% versus ≤4%) and SGA category indicated that patients with early decrease (≥5%) of HDL-C had significantly higher decrease of HDL-C (16.2%; p=0.02) after 3 months of treatment as compared to patients without early changes of HDL-C (Supplementary Table 4 ). In addition, trends of difference for TC and non-HDL-C increase after 3 months of SGA treatment were also observed between patients with and without early increase of TC and non-HDL-C. Analyses could not be conducted for TG increase due to an insufficient number of observations. Of note, as compared to females, males had a significantly larger decrease of HDL-C levels (-13%; p = 0.04) and lower increase of TC levels (-15%; p=0.05) after 3 months of treatment (data not shown).
Influence of short-term lipid changes on new-onset dyslipidemia
Among the 53 young patients monitored during treatment with SGA, twenty-four had available data for survival analyses, which were used to characterize the development of new-onset dyslipidemia from 3 months of treatment (IQR: 80-101 days, range 56-447 days) (Supplementary Figure 1) . Demographic and clinical characteristics of patients whose baseline lipid levels were within the normal range are indicated in Supplementary Table 5 . The proportion of patients who met criteria for dyslipidemia at or after 3 months of SGA treatment ranged from 8% (2/24), 8% (2/25), 9% (2/21), 13% (3/24) to 33% (8/24) for LDL-C, non-HDL-C, HDL-C, TG and TC, respectively. Of note, analyses conducted in a higher number of patients (n=79) whose lipid levels at first month were not necessarily available (and whose baseline lipid levels were within the normal range) showed similar findings, i.e. dyslipidemia incidences of 23%, 11%, 5%, 7% and 6% for TC, LDL, TG, HDL and non-HDL, respectively.
Baseline TC and LDL-C levels were significantly higher in patients who developed dyslipidemia as compared to those who did not (p ≤ 0.02). In addition, patients developing TC hypercholesterolemia were more likely to be female (p = 0.009). Finally, although age range was narrow in the present psychiatric sample, patients developing TC hypercholesterolemia were significantly older as compared to those who did not (p = 0.05). Of note, a trend was also observed for higher age to be associated with an increased risk of LDL and non-HDL hypercholesterolemia (p = 0.06).
Development of new-onset dyslipidemia during treatment with SGA is displayed in Figure 1 . As the incidence of dyslipidemia for LDL-C, TG, HDL-C, and non-HDL-C was insufficient to perform multivariate analyses, Cox regression was only conducted on TC. Table 2 shows that females were significantly more prone to develop a TC hypercholesterolemia compared to males (p = 0.01). In addition, patients whose TC levels increased by ≥ 5% during the first month of treatment had a greater susceptibility to develop TC hypercholesterolemia as compared to others (p = 0.02). Although large confidence intervals were observed due to a small sample size, survival rate curves were significantly divided over time, depending on gender, and a trend of difference was observed for early thresholds of TC increase (Supplementary Figure 2) .
DISCUSSION
In the present sample of adolescent patients receiving SGA, a worrisome hypercholesterolemia prevalence of 17% for total cholesterol was observed at baseline, which is comparable to baseline results from a retrospective study including first episode patients aged 23.6 years (SD = 5 years) 27 . A Spanish pediatric study observed a higher proportion of hypercholesterolemia at baseline (26%) 36 , possibly attributable to less stringent criterion used to define hypercholesterolemia (i.e., ≥170 mg/dL; corresponding to 4.4 mmol/l). In adult patients included in our department, a much higher prevalence of baseline hypercholesterolemia was observed (38% 31 ), which can be explained by a longer duration of illness and of lifetime exposure to psychotropic treatment.
In the present study, almost half of the adolescents had early lipid changes of ≥ 5% (i.e. 49%, 43%, 36%, 28%, and 45% for TC, LDL-C, TG, HDL-C, and non-HDL-C, respectively), which is comparable with the proportions previously observed in adults (43%, 43%, 57%, 42%, and 47%, respectively) 31 . Adolescent patients whose lipid levels changed by ≥ 5% during the first month appeared to have higher changes of lipid levels and a greater tendency to develop hypercholesterolemia during the course of a long-term treatment, as compared to patients whose early lipid levels changed by < 5%. In accordance with a previous study conducted in our department, which included mainly adult patients 31 , the risk of developing hypercholesterolemia was significantly greater for females than for males. These findings are also consistent with results from a retrospective adolescent cohort 24 and with other studies, albeit controversial, suggesting that women have a greater vulnerability to develop psychotropic drug-induced metabolic disturbances than men 12, 17, 45 .
In the present study, young females had higher levels of total cholesterol than young males, in agreement with results from a recent study on adolescent psychiatric inpatients 20 . Multivariate analyses showed that young females and patients with early increase in TC were more likely to develop new-onset hypercholesterolemia as compared to others. On the other hand, previous analyses in a sample including a higher number of patients (aged 13-89 years) showed that males were more prone than females to develop HDL hypocholesterolemia during treatment with psychotropic The findings of the present study need to be considered with some limitations. First, although the median age was low, the majority of patients were not drug naïve, and the observed lipid levels increase may have resulted from past treatments. However, the naturalistic setting of the present study strengthens the clinical validity of the present findings. Second, information on environmental changes, such as physical exercise or diet habits throughout the treatment, which could have influenced the evolution of lipid levels, were not available and, therefore, not taken into account. Third, a considerable drop-out rate was observed during the prospective study, reducing the number of available observations after three months of treatment, possibly attributable to psychiatry-related factors, such as treatment switching, poor medication adherence, and/or refusal of patients participate in follow-up. In addition, medication adherence was not guaranteed, which could lead to the inclusion of some false negatives, for example, patients who did not develop adverse lipid effects because they did not take the drug. However, exclusion of such patients might have led to even worse lipid outcomes. Finally, in the present study, no patients received other drugs than SGAs (i.e. first generation antipsychotics, mood stabilizers or antidepressants). Then, studies including adolescents receiving other drugs than SGAs should also be performed to evaluate their impact on the worsening of the lipid profile.
In conclusion, this study underlines the importance of metabolic monitoring following the introduction of SGA in young patients who are particularly susceptible to adverse metabolic effects. Further research should focus on finding effective interventions to prevent such adverse effects. In case of metabolic disturbance, if clinically possible, the causative SGA should be replaced after a careful evaluation of the risk-benefit ratio of a drug switch. Considering the major impact of dyslipidemia and its important consequences on morbidity and mortality, it is critical that healthcare professionals are aware of the risks associated with the prescription of SGA.
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CLINICAL POINTS
Although early changes of the lipid profile during treatment with psychotropic drugs were demonstrated in adults, this side effect has never been evaluated in adolescent patients.
Considering the major impact of dyslipidemia on morbidity and mortality, it is critical that healthcare professionals monitor and control lipid levels in young patients receiving psychotropic treatments that induce metabolic side effects. clozapine, mirtazapine and quetiapine versus other drugs). P-values in bold are significant. Analyses on triglyceride could not be performed due to a too low number of observations.
Abbreviations: HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; non-HDL-C: non-high-density lipoprotein cholesterol; TC: total cholesterol; TG:
triglycerides. Only patients with no dyslipidemia at baseline are included. P-values were calculated using rank-sum tests (for continuous variables) and chi 2 tests (for categorical variables) between groups. Values in bold are significant.
Supplementary
a Levels of TC for NODTC groups, LDL-C for NODLDL groups, TG for NODTG groups, HDL-C for NODHDL groups and non-HDL-C for NODnonHDL groups.
